Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (326)	8/29/1998 4:50:00 AM
From: s jones	Read Replies (1) \| Respond to of 645

24 August 1998 Melbourne, Australia -- Biota Holdings Limited today announced that clinical trial results of its influenza diagnostic test kit, AB FLU OIAr, will be presented at the prestigious Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego in September. A clinical investigator identified by Biota's partner, BioStar, will present the diagnostic trial results. The study concluded that the Biota/BioStar test offers rapid detection of influenza A and B in a variety of patients and specimen types. Biota is an Australian listed company (BTA), based in Melbourne and engaged in the funding and management of a research and development program focusing principally on the discovery of new human pharmaceuticals for the treatment of viral respiratory diseases and cancer. The Company's ADRs (BTAHY) trade in the US on the pink sheets at a ratio of three shares to each ADR